SCHEMBL1132582

SCHEMBL1132582

Oc1ccc(/C=N/Nc2nc3ccccc3s2)c(O)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 13/20 0.58
▸ KMT2A Q03164 11/20 0.58
▸ MEN1 O00255 10/20 0.58
▸ RAB9A P51151 9/20 0.58
▸ GAA P10253 9/20 0.58
▸ NPC1 O15118 9/20 0.58
▸ KDM4E B2RXH2 7/20 0.58
▸ MAPK1 P28482 5/20 0.58
▸ LMNA P02545 5/20 0.57
▸ TDP1 Q9NUW8 4/20 0.57
▸ POLB P06746 3/20 0.57
▸ HTT P42858 3/20 0.57
▸ L3MBTL1 Q9Y468 2/20 0.57
▸ MGAM O43451 1/20 0.57
▸ SMN1; SMN2 Q16637 7/20 0.56
▸ NFKB1 P19838 4/20 0.56
▸ NFKB2 Q00653 4/20 0.56
▸ RELA Q04206 4/20 0.56
▸ NPSR1 Q6W5P4 3/20 0.56
▸ PAX8 Q06710 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1132583 1.00 MAPT (0.58) MAPTKMT2AMEN1RAB9AGAA
SCHEMBL15965635 0.91 MAPT (0.60) MAPTKMT2AMEN1RAB9AGAA
SCHEMBL1164673 0.86 MBD2 (0.65) MAPTKMT2AMEN1RAB9AGAA
SCHEMBL1164671 0.86 MBD2 (0.65) MAPTKMT2AMEN1RAB9AGAA
SCHEMBL1165591 0.83 MAPT (0.68) MAPTKMT2AMEN1RAB9AGAA
SCHEMBL1165592 0.83 MAPT (0.68) MAPTKMT2AMEN1RAB9AGAA
SCHEMBL15494570 0.82 MAPT (0.61) MAPTKMT2AMEN1RAB9AGAA
SCHEMBL21010612 0.82 MAPT (0.68) MAPTKMT2AMEN1RAB9AGAA
SCHEMBL13779288 0.80 MAPT (0.75) MAPTKMT2AMEN1RAB9AGAA
SCHEMBL13780382 0.79 MAPT (0.70) MAPTKMT2AMEN1RAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9512066-B2 Enhancers of protein degradation MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2016-12-06 — — US claimed
US-20120282629-A1 Enhancers of Protein Degradation MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2012-11-08 — — US claimed
EP-2488485-A1 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2012-08-22 — — EP claimed
WO-2011020883-A9 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2012-07-12 — — WO claimed
WO-2011020883-A1 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2011-02-24 — — WO claimed
EP-2287149-A1 Enhancers of protein degradation MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) 2011-02-23 — — EP claimed
US-10647794-B2 Polymerizable compound, polymerizable composition, polymer, and optically anisotropic material ZEON CORPORATION (JP) 2020-05-12 — — US disclosed
US-9512066-B2 Enhancers of protein degradation MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2016-12-06 — — US disclosed
US-9447059-B2 Intermediate for manufacture of polymerizable compound and process for manufacture thereof ZEON CORPORATION (JP) 2016-09-20 — — US disclosed
US-9447059-B2 Intermediate for manufacture of polymerizable compound and process for manufacture thereof ZEON CORPORATION (JP) 2016-09-20 — — US disclosed
US-20160145363-A1 POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, AND OPTICALLY ANISOTROPIC MATERIAL ZEON CORPORATION (JP) 2016-05-26 — — US disclosed
US-20160145363-A1 POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, AND OPTICALLY ANISOTROPIC MATERIAL ZEON CORPORATION (JP) 2016-05-26 — — US disclosed
US-9207360-B2 Polymerizable compound, polymerizable composition, polymer, and optically anisotropic body ZENO CORPORATION (JP) 2015-12-08 — — US disclosed
US-20140142266-A1 POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, AND OPTICALLY ANISOTROPIC BODY ZEON CORPORATION (JP) 2014-05-22 — — US disclosed
US-20140142266-A1 POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, AND OPTICALLY ANISOTROPIC BODY ZEON CORPORATION (JP) 2014-05-22 — — US disclosed
US-20120282629-A1 Enhancers of Protein Degradation MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2012-11-08 — — US disclosed
EP-2488485-A1 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2012-08-22 — — EP disclosed
WO-2011020883-A9 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2012-07-12 — — WO disclosed
WO-2011020883-A1 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2011-02-24 — — WO disclosed
EP-2287149-A1 Enhancers of protein degradation MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) 2011-02-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120282629-A1 Enhancers of Protein Degradation HTT, HYPK, TFEB MAPT 149/4885KMT2A 2000/4885MEN1 3413/4885
US-20160145363-A1 POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, AND OPTICALLY ANISOTROPIC MATERIAL F12, C1S, C5 MAPT 347/4885KMT2A 1851/4885MEN1 2122/4885
US-10647794-B2 Polymerizable compound, polymerizable composition, polymer, and optically anisotropic material C1S, F12, C5 MAPT 564/4885KMT2A 1805/4885MEN1 1440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback